ABSTRACT
We report a case of itchy papulovesicular rash consistent with varicella-zoster virus reactivation after Pfizer-BioNTech vaccine second dose administration. While there have been cases of varicella-zoster virus reactivation due to COVID-19 or COVID-19 vaccine inoculation in older individuals with pre-existing conditions, this case report describes the first case of varicella-zoster virus reactivation on a healthy, young male in the absence of pre-existing conditions. The mechanisms underlying varicella-zoster virus reactivation in patients with COVID-19 are unknown and should be further characterized.
Subject(s)
COVID-19 Vaccines/adverse effects , Chickenpox/etiology , Chickenpox/virology , Herpesvirus 3, Human , Adult , BNT162 Vaccine , COVID-19 Vaccines/administration & dosage , Chickenpox/pathology , Humans , Male , Skin/pathology , Vaccination/adverse effectsABSTRACT
Long-term and rare adverse effects of COVID-19 vaccines are unknown. Hence, it is important to report them to improve the safety profile of the vaccines and enhance their use worldwide. Here, we describe a case of acute visual impairment after Pfizer-BioNTech vaccine second dose.